Research for treatments, prevention and a cure
Page template: single-clinical-trials.php
Search terms : 

Clinical Trials

  • Clinical Studies

Vaccines and Immunotherapies (VIT)

CTN 239: Phase II study of AGS-004 an immunotherapeutic agent in combination with ART followed by ART interruption

Trial results

Print Friendly, PDF & Email

A phase II study testing the activity and safety of AGS-004 as an immunotherapeutic in successfully ART-treated subjects infected with HIV-1 in combination with ART followed by ART interruption


CTN 239 aimed to assess the efficacy and safety of a personalized immunotherapy during a 12-week ART structured treatment interruption. This was a two-year, open label (where both the investigator and participant knew who is receiving the experimental drug) examination of the ability of AGS-004 to improve immune control of viral replication.

Study Design

Following screening and leukopheresis, participants received one injection of 0.6 ml AGS-004 every four weeks four times while continuing on ART. At week 12, participants with a viral load of less than 1000 copies/ml continued with AGS-004 and an ART interruption. At week 26, participants discussed with the study doctor, according to their viral load rebound, whether to continue with AGS-004 or restart ART alone.

The study agent, AGS-004, is created from a person’s own dendritic cells—white blood cells that stimulate the body’s immune system—and a sample of their HIV virus. This is the first experimental treatment designed from a person’s HIV genetic material and their body’s cells.


Forty-seven participants who were on their first antiretroviral drug regimen and had a CD4 cell count greater than or equal to 450 cells/mm3 for at least three months before study onset were recruited for the study.


Final analysis of this phase II study of an autologous dendritic cell immunotherapy (AGS-004) showed positive outcomes in primary endpoint of viral load control.


Researchers concluded that the experimental treatment resulted in an unexpectedly long delay in viral rebound, time to peak viral load during structured treatment interruption and a reduced viral load when compared to pre-ART levels.

Additional Information


Routy JP, Boulassel MR, Nicolette CA, Jacobson JM. Assessing risk of a short-term antiretroviral therapy discontinuation as a read-out of viral control in immune-based therapy. J Med Virol. 2012;84(6):885-9.

Principal Investigator

Dr. Jean-Pierre Routy

Latest News

In Memoriam: Dr. David Cooper

| Uncategorized | No Comments

The CTN offers condolences to the family, friends, and colleagues of Dr. David Cooper. Dr. Cooper dedicated his life to…

Trans Working Group Working To Remove Health Care Barriers

| Uncategorized | No Comments

  The Prevention and Vulnerable Populations (PVP) Core’s Trans Working Group has submitted their first grant proposal. The proposal is…

Canadian Guidelines on PrEP and nPEP Published

| Uncategorized | No Comments

After nearly two years of work and consultation, the first Canadian Guidelines on pre-exposure prophylaxis (PrEP) and non-occupational post-exposure prophylaxis…

Why do we need PrEP Guidelines? Ask an expert. VIDEO

| Uncategorized | No Comments

Despite efforts to reduce new incidences of HIV like condom campaigns, needle exchanges, and treatment as prevention, the actual number…

Research for treatments, prevention and a cure